Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Helen Nicole Toloui"'
Autor:
Robert Huddart, Vasiliki Michalarea, L Rhoda Molife, Saeed Rafii, Helen Nicole Toloui, Johann S. de Bono, Rajiv Kumar, Stanley B. Kaye, Udai Banerji, Karim Rihawi
Publikováno v:
Annals of Oncology. 25:iv300
Background: There are limited anticancer therapies available for BC. Novel targeted therapies (TT) may offer more treatment options. Methods: Retrospective data was collected on clinical treatment and tumour characteristics on patients (pts) with BC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a9b76250fc5989362ace4b122bca78e
https://doi.org/10.1093/annonc/mdu337.56
https://doi.org/10.1093/annonc/mdu337.56
Autor:
Johann S. de Bono, Géraldine Perkins, Penelope Flohr, Sadiya Saeed, Stanley B. Kaye, Helen Nicole Toloui, Amy Mulick Cassidy, Anne Mary Young, Michael Ong, L Rhoda Molife, Michael A Gonzalez, Udai Banerji, Kirsty Moran, Joaquin Mateo, Khurum Khan, Matthew C.H. Ng, Ruth Riisnaes, Timothy A. Yap, Khin Thway, Lorna Pope
Publikováno v:
Journal of Clinical Oncology. 30:6-6
6 Background: Previous studies suggest that tumoral cfDNA is a potential biomarker in cancer. Methods: Prospective collection of samples from patients (pts) referred to a phase I trials unit, in 2 cohorts: “A”(manual isolation of cfDNA, Sep09-Dec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::667bdef101cd161407d4369eab484b4c
https://doi.org/10.1200/jco.2012.30.30_suppl.6
https://doi.org/10.1200/jco.2012.30.30_suppl.6
Autor:
Kirsty Moran, Amy Mulick Cassidy, Stanley B. Kaye, Timothy A. Yap, Jen Kate Lewis, Ruth Riisnaes, Géraldine Perkins, Jesus Corral Jaime, Sadiya Saeed, Michael Ong, Helen Nicole Toloui, L Rhoda Molife, Khin Thway, Lorna Pope, Udai Banerji, Joaquin Mateo, K. A. Denholm, Andrea Biondo, Penelope Flohr, Johann S. de Bono
Publikováno v:
Journal of Clinical Oncology. 30:10525-10525
10525 Background: Studies suggest that tumoral cfDNA can be isolated from plasma and used as a biomarker. Methods: We conducted a prospective study in adult pts with advanced cancer referred for phase I clinical trials Sep09-Dec10 (A: Pilot Phase n=1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a221876a07a0c9f806c0e34badf146bf
https://doi.org/10.1200/jco.2012.30.15_suppl.10525
https://doi.org/10.1200/jco.2012.30.15_suppl.10525
Autor:
L Rhoda Molife, Begona Jimenez Rodriguez, Udai Banerji, David Lorente, Helen Nicole Toloui, Stan B. Kaye, Johann S. de Bono, Hasina Hassam, Caroline O. Michie, Debarati Goswami, Jimena Lovosgaldeano
Publikováno v:
ResearcherID
9590 Background: Phase I trials (PhIT) participants are those who have exhausted standard treatment (tx) or for whom no standard tx exists; most patients (pts) are unlikely to benefit from new drugs. Response rate and median overall survival (OS) are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2b8aa675cb6e4bace8d41804e5098ee
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000358613204474&KeyUID=WOS:000358613204474
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000358613204474&KeyUID=WOS:000358613204474
